161 related articles for article (PubMed ID: 23999912)
1. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
Mago R; Forero G; Greenberg WM; Gommoll C; Chen C
Clin Drug Investig; 2013 Oct; 33(10):761-71. PubMed ID: 23999912
[TBL] [Abstract][Full Text] [Related]
2. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
3. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
4. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
5. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
7. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Bruno A; Morabito P; Spina E; Muscatello MR
Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Blum SI; Tourkodimitris S; Ruth A
J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
[TBL] [Abstract][Full Text] [Related]
9. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Saraceni MM; Venci JV; Gandhi MA
J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Montgomery SA; Mansuy L; Ruth AC; Li D; Gommoll C
Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
Sambunaris A; Gommoll C; Chen C; Greenberg WM
Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
[TBL] [Abstract][Full Text] [Related]
13. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
14. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen L; Greenberg WM; Gommoll C; O'Connor J; Zukin SR; Periclou A; Ghahramani P
Clin Ther; 2015 Sep; 37(9):2059-70. PubMed ID: 26256429
[TBL] [Abstract][Full Text] [Related]
15. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
Durgam S; Chen C; Migliore R; Prakash C; Thase ME
Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739
[TBL] [Abstract][Full Text] [Related]
16. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.
Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S
CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
Montgomery SA; Gommoll CP; Chen C; Greenberg WM
CNS Spectr; 2015 Apr; 20(2):148-56. PubMed ID: 24902007
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
20. Levomilnacipran extended release: first global approval.
Hair P; Cameron F; Garnock-Jones KP
Drugs; 2013 Sep; 73(14):1639-45. PubMed ID: 24000002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
